- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ipsen SA (IPN)
Ipsen SA stock price live, this page displays EPA IPN stock exchange data. View the IPN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ipsen SA real time stock price chart below.
What Is the Ipsen SA Stock Price Today?
The Ipsen SA stock price today is 120.00.
What Is the Stock Symbol for Ipsen SA?
The stock symbol for Ipsen SA is "IPN."
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Paris stock exchange.
Is Ipsen SA a Good Stock to Buy?
Determining whether Ipsen SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPN quote. (ISIN: FR0010259150)
What Is the Ipsen SA Stock Price Today?
The Ipsen SA stock price today is 120.00.
What Is the Stock Symbol for Ipsen SA?
The stock symbol for Ipsen SA is "IPN."
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Paris stock exchange.
Is Ipsen SA a Good Stock to Buy?
Determining whether Ipsen SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPN quote. (ISIN: FR0010259150)
120.00
+0.60(+0.50%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118.70
120.00
52 wk Range
87.95
131.60
IPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118.70120.00
52 wk Range
87.95131.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.17%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.17%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
130.07
Upside
+8.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Ipsen SA Company Profile
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company was founded in 1929 and is headquartered in Paris, France.
Ipsen SA Earnings Call Summary for Q3/2025
- Q3 2025 revenue of €915M beat forecasts by 5.05%, driving stock up 5.39% to €119.20
- Full-year 2025 guidance upgraded to 10% sales growth; strong performance in oncology and rare diseases
- Core operating margin expected around 35% of total sales; portfolio ex-Somatuline grew 12.3% YTD
- Multiple pipeline catalysts anticipated in 2026; company exploring M&A in oncology and rare diseases
- CEO David Loew: 'We continue to deliver strong momentum and remain firmly on track to achieve our ambitions'
Last Updated: 2025-10-22, 08:12 a/m
Read Full TranscriptCompare IPN to Peers and Sector
Metrics to compare | IPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.0x | 23.6x | −0.6x | |
PEG Ratio | −0.65 | 0.10 | 0.00 | |
Price/Book | 2.3x | 5.1x | 2.6x | |
Price / LTM Sales | 2.6x | 2.4x | 3.2x | |
Upside (Analyst Target) | 5.4% | 10.5% | 41.8% | |
Fair Value Upside | Unlock | 19.5% | 5.3% | Unlock |
Analyst Ratings
6 Buy
6 Hold
2 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 130.07
(+8.39% Upside)
Earnings
Latest Release
Oct 22, 2025
EPS / Forecast
-- / --
Revenue / Forecast
915.00M / 871.00M
People Also Watch
FAQ
What Is the Ipsen (IPN) Stock Price Today?
The Ipsen stock price today is 120.00
What Stock Exchange Does Ipsen Trade On?
Ipsen is listed and trades on the Paris Stock Exchange stock exchange.
What Is the Stock Symbol for Ipsen?
The stock symbol for Ipsen is "IPN."
Does Ipsen Pay Dividends? What’s The Current Dividend Yield?
The Ipsen dividend yield is 1.17%.
What Is the Ipsen Market Cap?
As of today, Ipsen market cap is 9.85B.
What Is Ipsen's Earnings Per Share (TTM)?
The Ipsen EPS (TTM) is 5.37.
When Is the Next Ipsen Earnings Date?
Ipsen will release its next earnings report on Feb 12, 2026.
From a Technical Analysis Perspective, Is IPN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Ipsen Stock Split?
Ipsen has split 0 times.
How Many Employees Does Ipsen Have?
Ipsen has 5358 employees.
What is the current trading status of Ipsen (IPN)?
As of Dec 27, 2025, Ipsen (IPN) is trading at a price of 120.00, with a previous close of 119.40. The stock has fluctuated within a day range of 118.70 to 120.00, while its 52-week range spans from 87.95 to 131.60.
What Is Ipsen (IPN) Price Target According to Analysts?
The average 12-month price target for Ipsen is EUR130.07143, with a high estimate of EUR154 and a low estimate of EUR105. 6 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +8.39% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.